Summit Therapeutics (SMMT) Net Cash Flow Growth (3y) (2022 - 2026)
Powered by 
Analysis
Summit Therapeutics (SMMT) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 52.78% |
| 10 | Summit Therapeutics | 13.67 Bn | 12.98 Bn | - | 133.52% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 133.52% |
| Mar 31, 2026 | 41.00% |
| Dec 31, 2025 | -26.52% |
| Sep 30, 2025 | -42.49% |
| Jun 30, 2025 | 85.88% |
| Mar 31, 2025 | 163.54% |
| Dec 31, 2024 | 50.27% |
| Sep 30, 2024 | 69.27% |
| Jun 30, 2024 | -256.79% |
| Mar 31, 2024 | -31.58% |
| Dec 31, 2023 | 3.65% |
| Sep 30, 2023 | -2.84% |
| Jun 30, 2023 | -16.02% |
| Mar 31, 2023 | -302.85% |
| Dec 31, 2022 | 109.54% |
| Mar 31, 2022 | -25.77% |